Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis - Trial NCT05705414
Access comprehensive clinical trial information for NCT05705414 through Pure Global AI's free database. This Phase 1 trial is sponsored by The University of Texas Health Science Center at San Antonio and is currently Not yet recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 28 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The University of Texas Health Science Center at San Antonio
Timeline & Enrollment
Phase 1
Jul 01, 2023
Aug 01, 2024
Primary Outcome
Brief Fatigue Inventory (BFI) score
Summary
The study will test and compare the efficacy of a single essential amino acid valine with a
 combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive
 function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05705414
Non-Device Trial